Presidio Management Group X. Ll Sells 14,086 Shares of eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) Stock

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTRGet Rating) major shareholder Presidio Management Group X. Ll sold 14,086 shares of the stock in a transaction that occurred on Wednesday, May 18th. The stock was sold at an average price of $1.73, for a total value of $24,368.78. Following the completion of the transaction, the insider now directly owns 136,507 shares of the company’s stock, valued at $236,157.11. The sale was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

EFTR stock traded up $0.02 during midday trading on Thursday, hitting $1.72. 21,775 shares of the company’s stock were exchanged, compared to its average volume of 30,974. The stock’s fifty day moving average price is $3.49 and its 200-day moving average price is $5.67. The company has a debt-to-equity ratio of 0.75, a quick ratio of 18.38 and a current ratio of 18.38. eFFECTOR Therapeutics, Inc. has a one year low of $1.63 and a one year high of $40.42.

eFFECTOR Therapeutics (NASDAQ:EFTRGet Rating) last posted its earnings results on Wednesday, March 16th. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.69. The business had revenue of $0.31 million for the quarter. As a group, research analysts forecast that eFFECTOR Therapeutics, Inc. will post -0.52 earnings per share for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC acquired a new stake in shares of eFFECTOR Therapeutics in the 3rd quarter valued at about $187,000. Northern Trust Corp acquired a new stake in shares of eFFECTOR Therapeutics in the 4th quarter valued at about $138,000. State Street Corp acquired a new stake in shares of eFFECTOR Therapeutics in the 1st quarter valued at about $68,000. Jane Street Group LLC acquired a new stake in shares of eFFECTOR Therapeutics in the 3rd quarter valued at about $257,000. Finally, Geode Capital Management LLC acquired a new stake in shares of eFFECTOR Therapeutics in the 3rd quarter valued at about $337,000. 51.71% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts recently weighed in on EFTR shares. Credit Suisse Group dropped their price target on eFFECTOR Therapeutics from $16.00 to $14.00 and set an “outperform” rating for the company in a report on Thursday, March 17th. Zacks Investment Research raised eFFECTOR Therapeutics from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a research note on Friday, May 13th. Stifel Nicolaus cut eFFECTOR Therapeutics from a “buy” rating to a “hold” rating and lowered their target price for the company from $20.00 to $6.20 in a research note on Tuesday, January 25th. Finally, JMP Securities reissued a “buy” rating and issued a $8.00 target price on shares of eFFECTOR Therapeutics in a research note on Monday, April 11th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $16.78.

About eFFECTOR Therapeutics (Get Rating)

eFFECTOR Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer.

Further Reading

Insider Buying and Selling by Quarter for eFFECTOR Therapeutics (NASDAQ:EFTR)

Receive News & Ratings for eFFECTOR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for eFFECTOR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.